Abstract:Escherichia coli is a gram-negative bacterium, an intestinal pathogen that can cause intestinal inflammation. Antimicrobial peptides are a class of small molecule peptides, which has good antibacterial activity against a variety of gram-positive and negative bacteria. In this regard, the authors aimed to study the effect of the antimicrobial peptide MPX, which was administered orally, on the intestinal wall of mice infected with the intestinal barrier function, which were infected with E. coli. Synthesis and purification of the antimicrobial peptide MPX (H-INWKGIAAMAKKLL-NH2) was performed by Jier Sheng Hua (Shanghai, China). Mass spectrometry and liquid chromatography (HPLC) were used for this purpose. Escherichia Coli (O157: H7 ATCC43889) was isolated from human faeces in which haemolytic uremic syndrome was reported. Solid LB agar (Solarbio, China) was used to isolate enterohemorrhagic E. coli. The culture was obtained from the Chinese Institute of Veterinary Drug Control (Beijing, China). The results of necropsy found that using of an orally administered MPX could alleviate the damage of E. coli to the liver, spleen, and the lungs were less affected. According to H&E results in case of an orally administered MPX group considerably relieved duodenum and organs on day 7 and day 28. qRT-PCR results showed orally administered MPX could reduce the inflammation-related factors in the mRNA expression of IL-2 and IL-6 and TNF-α on day 7 and day 28. In addition, orally administered MPX could significantly increase them RNA expression of tight junction proteins Occludin and Zo-1 on day 7 and day 28. The results of immune histochemistry further showed that an orally administered MPX could increase the mRNA expression of MUC2 in jejunum. The above results showed that orally administered MPX could alleviate the attack of E. coli on the intestinal tract of mice, relieve intestinal inflammation, and improve the intestinal barrier function. This study lays a theoretical foundation for adding antimicrobial peptides to food. In orally administered MPX authors can see reducing the mRNA expression of inflammation-related factors, thereby alleviating the intestinal inflammation caused by E. coli infection in mice. Authors can add that orally administered MPX shows an increase in mRNA expression of tight junction protein in intestines and improves the intestinal barrier function. This study lays the foundation for adding antimicrobial peptides to food to relieve inflammation and improve barrier function in clinical practices

Antimicrobial Peptide MPX Against Escherichia Coli O157:H7 Infection and Inhibiting inﬂammation, Enhancing Epithelial Barrier and Promoting Nutrient Absorption in the Intestine

Antimicrobial Peptide MPX&nbsp;Against Escherichia Coli O157:H7&nbsp;Infection and Inhibiting inﬂammation, Enhancing Epithelial Barrier and Promoting Nutrient Absorption in the Intestine

The Antimicrobial Peptide Mastoparan X Protects Against Enterohemorrhagic Escherichia coli O157:H7 Infection, Inhibits Inflammation, and Enhances the Intestinal Epithelial Barrier

The Effect of Oral Administration of the Antibacterial Peptide MPX on Intestinal Inflammation of Mice in Experimental Infection with Escherichia Coli Strain O157: H7

Antimicrobial peptide Mastoparan X has good activity against Escherichia coli in vitro and alleviates its pathogenicity in mice

Oral Administration of the Antimicrobial Peptide Mastoparan X Alleviates Enterohemorrhagic Escherichia Coli–induced Intestinal Inflammation and Regulates the Gut Microbiota

Antimicrobial Peptide MPX with Broad-Spectrum Bactericidal Activity Promotes Proper Abscess Formation and Relieves Skin Inflammation

Protective Ability of Biogenic Antimicrobial Peptide Microcin J25 Against Enterotoxigenic Escherichia Coli-Induced Intestinal Epithelial Dysfunction and Inflammatory Responses IPEC-J2 Cells

Lasso Peptide Microcin J25 Effectively Enhances Gut Barrier Function and Modulates Inflammatory Response in an Enterotoxigenic Escherichia Coli-Challenged Mouse Model

A Novel Cecropin-LL37 Hybrid Peptide Protects Mice Against EHEC Infection-Mediated Changes in Gut Microbiota, Intestinal Inflammation, and Impairment of Mucosal Barrier Functions

The Efficacy of Anti-Proteolytic Peptide R7I in Intestinal Inflammation, Function, Microbiota, and Metabolites by Multi-Omics Analysis in Murine Bacterial Enteritis

The Antimicrobial Peptide MPX Kills Actinobacillus Pleuropneumoniae and Reduces Its Pathogenicity in Mice.

Effects of the Antimicrobial Peptide Mastoparan X on the Performance, Permeability and Microbiota Populations of Broiler Chickens

Therapeutic administration of the recombinant antimicrobial peptide microcin J25 effectively enhances host defenses against gut inflammation and epithelial barrier injury induced by enterotoxigenic <i>Escherichia coli</i> infection

The antibacterial activity and mechanism of a novel peptide MR-22 against multidrug-resistant Escherichia coli

The Antimicrobial Peptide MPX Can Kill Staphylococcus aureus, Reduce Biofilm Formation, and Effectively Treat Bacterial Skin Infections in Mice

Antibacterial and Antibiofilm Activities of Novel Antimicrobial Peptides against Multidrug-Resistant Enterotoxigenic Escherichia Coli

Protective effect of plantaricin bio-LP1 bacteriocin on multidrug-resistance Escherichia Coli infection by alleviate the inflammation and modulate of gut-microbiota in BALB/c mice model

β-defensin 118 attenuates inflammation and injury of intestinal epithelial cells upon enterotoxigenic Escherichia coli challenge

Exploring PLGA-OH-CATH30 Microspheres for Oral Therapy of Escherichia coli-Induced Enteritis

Pediococcus pentosaceus IM96 Exerts Protective Effects against Enterohemorrhagic Escherichia coli O157:H7 Infection In Vivo